Rain Therapeutics Inc
Change company Symbol lookup
Select an option...
RAIN Rain Therapeutics Inc
SASOF Sasol Ltd
SMBC Southern Missouri Bancorp Inc
ALG Alamo Group Inc
AFFCF American Future Fuel Corp
TDS-U Telephone and Data Systems Inc
FRSH Freshworks Inc
TA Travelcenters of America Inc
WWW Wolverine World Wide Inc
$PABEZ5T Bloomberg PAB Eurozone 50 Decrement
Go

Health Care : Pharmaceuticals |
Company profile

Rain Therapeutics Inc. (Rain) is a late-stage precision oncology company developing therapies that target oncogenic drivers. The Company’s lead product candidate, Milademetan (RAIN-32) is a small molecule, oral inhibitor of mouse double minute 2 (MDM2), which may be oncogenic in numerous cancers. RAIN-32 is being evaluated in an ongoing Phase III clinical trial in patients with LPS, as well as a Phase II tumor-agnostic basket trial in certain solid tumors (MANTRA-2). Rain is commencing a Phase II clinical trial of milademetan (MANTRA-3), for the treatment of patients with Merkel cell carcinoma. In addition to RAIN-32, the Company is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52. The MANTRA-3 trial is designed to evaluate the efficacy of milademetan, as a monotherapy in patients with MCC. Rain is also developing a preclinical program focused on targeting RAD52 in the deoxyribonucleic acid damage repair pathway.

Closing Price
$7.72
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Heavy Day)
Volume:
190,063

10-day average volume:
135,936
190,063
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

The risk of loss in trading futures can be substantial. Clients must consider all relevant risk factors, including their own personal financial situation, before trading. Margin and level 2 options approval or higher is required. Not all account owners will qualify.

Dividends are converted to USD using the current rate of exchange at the end of the business day on the day the dividend went EX. Earnings are converted to USD using the current rate of exchange at the end of the business day on the day earnings were announced.

Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.